• https://akupadamu.kayongutarakab.go.id/css/demo/
  • https://unakiinsight.unaki.ac.id/wp-includes/demo/
  • https://packmem.ipmc.cnrs.fr/js/sgacor/
  • https://wa-api.wika.co.id/demo/
  • https://ppid.trenggalekkab.go.id/public/vendor/sdemo/
  • https://ppid.trenggalekkab.go.id/public/build/user/
  • https://desatlogobendung.gresikkab.go.id/assets/user/
  • https://setda.dairikab.go.id/wp-includes/demo/
  • https://bidpropamkaltara.com/
  • https://uniquetastefood.com/

    • This site is part of the Siconnects Division of Sciinov Group

    This site is operated by a business or businesses owned by Sciinov Group and all copyright resides with them.

    ADD THESE DATES TO YOUR E-DIARY OR GOOGLE CALENDAR

    Registration
    logo_not_found

    Recent Updates

    • Home
    • Recent Updates

    16 Jan
    2024

    Initiation of the tender procedure for mRNA COVID-19 vaccines by the Health Emergency Preparedness and Response Authority (HERA) of the European Commission (EC)

    Moderna welcomes the initiation of a tendering procedure for mRNA COVID-19 vaccinesReadmore

    14 Dec
    2023

    Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vaccine

    Moderna has submitted marketing authorizations globally for mRNA-1345 and continues to prepare for an expected 2024 marketing launchReadmore

    26 Oct
    2023

    Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

    Safety profile of the mRNA-based combination vaccine candidates consistent with the companies’ COVID-19 vaccineReadmore

    25 May
    2023

    Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19

    PAXLOVID is the first FDA-approved oral treatment for COVID-19; has been authorized for emergency use since December 2021Readmore

    04 Apr
    2023

    InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients

    Vilobelimab is the first authorized drug to control complement factor C5a, a protein that plays an important and often harmful role in the body´s immune responseReadmore

    Subscribe to our News & Updates